The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT).

ABSTRACT:

Aims/hypothesis

High-throughput metabolomics technologies in a variety of study designs have demonstrated a consistent metabolomic signature of overweight and type 2 diabetes. However, the extent to which these metabolomic patterns can be reversed with weight loss and diabetes remission has been weakly investigated. We aimed to characterise the metabolomic consequences of a weight-loss intervention in individuals with type 2 diabetes.

Methods

We analysed 574 fasted serum samples collected within an existing RCT (the Diabetes Remission Clinical Trial [DiRECT]) (N=298). In the trial, participating primary care practices were randomly assigned (1:1) to provide either a weight management programme (intervention) or best-practice care by guidelines (control) treatment to individu

SUBMITTER: Corbin LJ 

PROVIDER: S-EPMC10709482 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature